Review
KeynoteDrug metabolism in the paediatric population and in the elderly
Keynote
Section snippets
Drug metabolism
Metabolism renders drugs more water-soluble so that they can be easily excreted from the body after their desired effect has been exerted. This process occurs primarily in liver hepatocytes to generate metabolites that are inactive and relatively non-toxic; however, metabolites may occasionally be the source of toxic effects. For prodrugs, the parent drug is inactive but the metabolite is active. Drug metabolism mechanisms can be classified into phase I and phase II reactions, the former
Oxidative enzymes
A review paper on the ontogeny of human phase I oxidative enzymes has been recently written by Hines and McCarver [4].
Acetylation
Many drugs such as sulfamethazine, hydralazine, isoniazid, p-aminosalicylic acid, p-aminobenzoic acid, phenelzine or procainamide, as well as toxic agents are conjugated with an acetyl group. N-Acetyltransferase (NAT), a cytosolic enzyme, is widely distributed in mammalian tissues.
Paediatric population: The maturational development of acetylation reactions has been reviewed by Strolin Benedetti et al. [10]. Acetylation of p-aminobenzoic acid (NAT1) appears to be present in premature and
Conclusion
In this review, the key factors accounting for differences in drug/metabolite exposure, that is differences in drug metabolism (both qualitative and quantitative) at the extremes of age have been discussed. Numerous studies have demonstrated age-related changes in the pharmacokinetics of various drugs. However, it is difficult to differentiate the effect of age because of variations in enzyme activity from effects caused by other factors such as altered liver mass, liver blood flow and changes
Acknowledgement
The authors wish to thank Ms. M. Rovei for her assistance in the preparation of the manuscript.
MARGHERITA STROLIN BENEDETTI Margherita Strolin Benedetti (PhD Chemistry, University of Bologna) is the author of 450 publications in international journals, most in the area of biochemical pharmacology, enzymology, pharmacokinetics, drug metabolism and drug–drug interactions. She is presently Associate Director for Scientific Affairs in the Department of Non Clinical Development at UCB. She previously directed research groups in other international pharmaceutical companies, contributing to the
References (103)
Role of biokinetics in risk assessment of drugs and chemicals in children
Regulat. Toxicol. Pharmacol.
(2004)Pharmacokinetics in older persons
Am. J. Geriatr. Pharmacother.
(2004)Cytochrome P-450 expression in sudden infant death syndrome
Biochem. Pharmacol.
(1996)Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver
Biochem. Pharmacol.
(1995)New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology
Drug Discov. Today
(2006)Human hepatic cytochrome P4503A activity in the elderly
Mech. Ageing Dev.
(1992)Ontogenesis of monoamine oxidase-A and -B in the human brain frontal cortex
Brain Res.
(1989)Pharmacokinetics of chloramphenicol and chloramphenicol succinate in infants and children
J. Pediatr.
(1981)Comparative carboxylesterase activities in infant and adult liver and their in vitro sensitivity to chlorpyrifos oxon
Regul. Toxicol. Pharmacol.
(2005)The effect of age on pharmacokinetics of the local anesthetic drug articaine
Reg. Anesth. Pain Med.
(1999)
Age related differences in salicylamide and acetaminophen conjugation in man
J. Pediatr.
Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics
Expert Opin. Drug Metab. Toxicol.
Pharmacocinétique et biotransformation des médicaments chez l’enfant
Louvain Med.
The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes
J. Pharmacol. Exp. Ther.
In vivo age-related changes in hepatic drug-oxidizing capacity in humans
J. Clin. Pharm. Ther.
Pharmacokinetic and pharmacodynamics factors that can affect sensitivity to neurotoxic sequalae in elderly individuals
Environ. Health Perspect.
The effect of age on drug metabolism
Ped. Perinat. Drug Ther.
A review of developmental aspects of cytochrome P450
J. Child Adolescent Psychopharmacol.
The use of caffeine for enzyme assays: a critical appraisal
Clin. Pharmacol. Ther.
Differences in absorption, distribution, metabolism and excretion between the paediatric and the adult population
Expert Opin. Drug Metab. Toxicol.
Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults
Br. J. Clin. Pharmacol.
Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants
Pediatr. Res.
Influence of age, frailty and liver function on the pharmacokinetics of brofaromine
Eur. J. Clin. Pharmacol.
Bioequivalence revisited: influence of age and sex on CYP enzymes
Clin. Pharmacol. Ther.
Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers
Br. J. Clin. Pharmacol.
Developmental expression of cytochrome P450 enzymes in human liver
Pharmacol. Toxicol.
Coumarin 7-hydroxylase: characteristics and regulation in mouse and man
J. Irish Coll. Phys. Surg.
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians
J. Pharmacol. Exp. Ther.
The metabolism of coumarin
Drug metabolism and ageing
Br. J. Clin. Pharmacol.
Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility
Pharmacogenetics
Developmental expression of human hepatic CYP2C9 and CYP2C19
J. Pharmacol. Exp. Ther.
Pharmacokinetic observations of phenytoin disposition in the newborn and young infant
Arch. Dis. Child.
Human cytochrome P450 maximal activities in pediatric versus adult liver
Drug Metab. Dispos.
Liver function and Phase I drug metabolism in the elderly. A paradox
Drugs Aging
The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics
Clin. Pharmacokinet.
Plasma levels of citalopram enantiomers and metabolites in elderly patients
Psychopharmacol. Bull.
Pharmacokinetics and metabolism of oral midazolam in preterm infants
Br. J. Clin. Pharmacol.
Effect of age on in vitro triazolam biotransformation in male human liver microsomes
J. Pharmacol. Exp. Ther.
The influence of age and sex on the clearance of cytochrome P450 3A substrates
Clin. Pharmacokinet.
Erythromycin breath test results in elderly, very elderly, and frail elderly persons
Clin. Pharmacol. Ther.
Developmental aspects of the monoamine-degrading enzyme monoamine oxidase
Dev. Pharmacol. Ther.
Factors affecting the relative importance of amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans
J. Neural Transm.
Monoamine oxidase: from physiology and pathophysiology to the design and clinical application of reversible inhibitors
Development of new H1 antihistamines: the importance of pharmacokinetics in the evaluation of safe and therapeutically effective agents
Curr. Med. Chem. Anti-Inflammatory & Anti-Allergy Agents
Alcohol dehydrogenase activities in the human gastric mucosa: effects of Helicobacter pylori infection, sex, age, and the part of the stomach
Alcohol Clin. Exp. Res.
Influence of age, sex, and Helicobacter pylori infection before and after eradication on gastric alcohol dehydrogenase activity
Alcohol Clin. Exp. Res.
No sex and age influence on the expression pattern and activities of human gastric alcohol and aldehyde dehydrogenases
Alcohol Clin. Exp. Res.
Blood ethanol concentrations following oral ethanol ingestion: Influence of age and gender
Zeitschrift fuer Gastroenterologie
The association of age with the activity of alcohol dehydrogenase in human liver
Age Ageing
Cited by (0)
MARGHERITA STROLIN BENEDETTI Margherita Strolin Benedetti (PhD Chemistry, University of Bologna) is the author of 450 publications in international journals, most in the area of biochemical pharmacology, enzymology, pharmacokinetics, drug metabolism and drug–drug interactions. She is presently Associate Director for Scientific Affairs in the Department of Non Clinical Development at UCB. She previously directed research groups in other international pharmaceutical companies, contributing to the development of important drugs, and also worked as Research Assistant at the University of Geneva where she specialized in the study of drug metabolism with radiolabelled compounds.
RHYS WHOMSLEY Rhys Whomsley (PhD Chemistry/Pharmacology, University of Wales) is the author of more than 30 publications in the area of drug metabolism and transport, pharmacokinetics and enzyme inhibition or induction. He has over 20 years experience in both scientific and regulatory aspects of drug development, leading teams in the pharma industry, contract research and at the University of Wales, where he focused on the development of steroidogenic enzyme inhibitors in the treatment of hormone-dependent cancers. He is currently Senior Principal Scientist Non-Clinical Development at UCB.
MICHAEL CANNING Michael Canning (Veterinary Science, University of Bristol) is a veterinary pathologist by training and has over 17 years experience in non-clinical drug development and regulatory affairs with special interests in carcinogenicity and reproductive and juvenile toxicology. He is currently the Vice-president of Non-clinical Development at UCB having previously held positions in UK and continental Europe.